A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma
Neuro-Oncology Anywhere: Glioma Home-Based Sequential Therapy (GHoST) Protocol
Mayo Clinic
120 participants
Sep 12, 2025
INTERVENTIONAL
Conditions
Summary
This clinical trial tests how well a digital treatment platform using a mobile application works for the delivery of home-based sequential therapy in patients with glioma. Access to specialized neuro-oncology care in the United States for patients with glioma is critically deficient. Care at centers with neuro-oncology specialists is associated with improved survival outcomes, yet many patients have limited access due to distance, disease-related disability, or lack of financial resources. The application provides patients continuous access to their care team in the home setting. A digital treatment platform may increase clinical trial participation and accelerate development of novel therapeutics while addressing a great health disparity in patients with glioma.
Eligibility
Inclusion Criteria10
- Age ≥ 18 years
- Diagnosis of glioma and intention to treat with either new or ongoing systemic therapy for at least 6 months.
- NOTE: Patient may be enrolled following completion of surgery and/or radiation therapy for newly diagnosed or recurrent tumor.
- NOTE: Any number of prior recurrences is permitted
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, AND Karnofsky performance status (KPS) of ≥ 60
- Expected survival ≥ 6 months in the opinion of treatment team
- Willing and able to adhere with the protocol for the duration of the study including undergoing treatment, and attending scheduled visits, and examinations
- Negative pregnancy test ≤ 8 days prior to registration for persons of childbearing potential only
- Provide written informed consent
- Ability to complete assessments and questionnaires by themselves or with assistance
Exclusion Criteria2
- Pregnant or nursing, imprisoned, or lacking capacity for understanding
- Uncontrolled and/or intercurrent illness or other condition which limits safety of or compliance with study proceedings
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Receive standard of care chemotherapy
Undergo CT
Receive access to the remote chemotherapy management and patient monitoring platform
Undergo MRI
Ancillary studies
Ancillary studies
Undergo surveillance
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07074756